[18F]-FLT-PET/CT scans

Phase 1

NNational Cancer Institute (NCI)

[18F]-FLT-PET/CT scans is one of 20 therapeutic programs targeting Neurofibromatosis. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[2][1]

Indication

NeurofibromatosisCompleted

NeurofibromatosisPhase 1

Completed

Competition

Competitive Landscape

25 competitors in Neurofibromatosis

#DrugCompanyPhaseTrials

Rapamune

PPrism Pharmaceuticals

Paraplatin

Oncovin

EEastern Cooperative Oncology Group

Koselugo

3 5

Tykerb

GSK

Phase 2

1 6

Gleevec

Novartis

Phase 2

1 7

Afinitor

Novartis

Phase 2

1 8

Verzenio

Eli Lilly

Phase 2

—9

Selumetinib /m2

NNational Cancer Institute (NCI)

Phase 3

—10

Conmana

BBetta Pharmaceuticals Co., Ltd.

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Neurofibromatosis1 trial

Transformation of Plexiform Neurofibromas to Malignant Peripheral Nerve Sheath Tumors in Neurofibromatosis Type 1: Clinical, Histopathologic, and Genomic Analysis

Completed·NNational Cancer Institute (NCI)·Phase 1·NCT02211768·10 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for [18F]-FLT-PET/CT scans. U.S. National Library of Medicine, National Institutes of Health.
[2]
Open Targets Platform — Drug–disease associations for [18F]-FLT-PET/CT scans. EMBL-EBI & Wellcome Sanger Institute.
[3]
SEC EDGAR — National Cancer Institute (NCI) company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Highest Phase: Phase 1[1]
Company: NNational Cancer Institute (NCI)

[18F]-FLT-PET/CT scans

Status by Indication[2][1]

Competitive Landscape

Trials by Indication[1]

Neurofibromatosis1 trial

References

Drug Info

Quick Facts

Related News